FDA Requests Additional Authority Over Compounders
MAY 17, 2013
In testimony before a United States House Energy and Commerce subcommittee on April 16, 2013, FDA Commissioner Margaret Hamburg, MD, acknowledged that the agency could have taken more action against compounding pharmacies such as the New England Compounding Center, whose tainted steroids caused a deadly meningitis outbreak last fall. Nonetheless, Dr. Hamburg said the agency needs expanded authority in order to hold compounding pharmacies to stricter safety standards.
Dr. Hamburg expressed regret that the FDA had not been more aggressive, but said that it had held back out of concern that the FDA would be sued by the pharmacies it targeted. She testified that the agency needs the authority to require compounding pharmacies that make high-risk products to register with the agency and to submit to inspections and share their records, which currently requires a court order. In addition, she said that compounders should be forced to adhere to uniform federal safety procedures and, like large drug manufacturers, should be required to report problems with their products.
Republican members of the committee seemed wary of the request for increased authority, arguing that the agency had failed to act, despite many warnings of problems with compounding pharmacies, while Democratic members seemed more open to granting the additional authority.
Become A RESPIMAT T.O.P. Performer
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?